Core Insights - The eleventh batch of national procurement results indicates that a total of 14 companies qualified for the bidding of Dapagliflozin oral sustained-release formulation, with 7 companies winning the selection [1] - Dapagliflozin is one of the most anticipated products in this procurement batch, currently leading the Chinese pharmaceutical market for small molecule drugs with sales exceeding 8 billion RMB [1] - The projected sales for public hospitals in 2024 for Dapagliflozin are estimated at 5.352 billion RMB, making it the only product in this procurement batch with annual sales exceeding 5 billion RMB [1] Company Summary - The companies that received the selection qualification include Hetero Labs Limited, Nanjing Fangsheng Pharmaceutical Technology Co., Ltd. (with Yiling Wanzhou International Pharmaceutical Co., Ltd. and Jiangsu Litai'er Pharmaceutical Co., Ltd. as contract manufacturers), Shandong Lukang Pharmaceutical Co., Ltd., Beijing Weilin Hengchang Pharmaceutical Technology Co., Ltd. (with Beijing Jingfeng Pharmaceutical Group Co., Ltd. as a contract manufacturer), M/s Cipla Ltd., Jiutian Pharmaceutical, and Hebei Zhiheng Pharmaceutical Co., Ltd. (with Xinhua Pharmaceutical (Gaomi) Co., Ltd. as a contract manufacturer) [1] - Among the selected companies, two are Indian pharmaceutical enterprises [1]
第十一批国采：7家企业拟中选达格列净口服常释剂 包括两家印度外企
Xin Lang Cai Jing·2025-10-28 11:10